Review
This narrative review aims to frame the evolution of the debated concept of clinical remission as an ambitious and now concretely achievable outcome in modern asthma management, to highlight correct management of inhaled therapies, oral corticosteroids and biological drugs in this context, and, finally, to provide clinicians with insights that could be useful to achieve remission in the greatest possible number of patients.
Case Series
This case series presents and discusses real-life experiences with using an hypochlorous acid (HOCl) ophthalmic spray to manage eye infections, further characterizing the use of HOCl for ophthalmic applications.
Corrigendum
The authors wish to make the following corrections to their article: Efimov SV, Matsiyeuskaya NV, Boytsova OV, et al. Corrigendum: The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study. Drugs in Context 2021; 10: 2021-11-1. DOI: 10.7573/dic.2020-11-1
Original Research
The aim of this study was to observe the safety and efficacy of AZB as an addition to the complex treatment of patients hospitalized with COVID-19. This study is the first exploratory
use of AZB in patients with COVID-19.
Review
In this review, the different biological options available for the treatment of severe refractory asthma, their mechanism of action, and the overlapping aspects of their usage in clinical practice are discussed.
